Loading stock data…
20/20 Biolabs (AIDX)
$0.60+0.01 (+1.58%)
Pre-Market$0.57-0.03 (-4.37%)· Last close Jun 26
20/20 Biolabs, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $353,375↓ | $538,274 | — | $553,820↑ | $536,084 |
| Gross Profit | $62,884↓ | $130,417 | — | $165,795↑ | $163,030 |
| Operating Income | -$1.44M↓ | -$912,846 | — | -$772,180↑ | -$1.24M |
| Net Income | -$2.17M↓ | -$1.31M | — | -$764,577↑ | -$1.25M |
Peer Comparison
JNJUNHPFE
Fundamentals
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for L...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.05M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-199.35%
Volume
Today's trading volume
152,870
